Hypertension after experimental cerebral ischemia: Candesartan provides neurovascular protection

Journal of Hypertension

Volumn 24, Issue 3, 2006, Pages 535-539

  Fagan, Susan C ^a,b,c   Kozak, Anna ^a,b   Hill, William D ^b   Pollock, David M ^b   Xu, Lin ^b   Johnson, Maribeth H ^b   Ergul, Adviye ^a,b   Hess, David C ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Candesartan; Hypertension; Stroke; Vascular protection

Indexed keywords

CANDESARTAN; HEMOGLOBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRAIN FUNCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EDEMA; HEMOGLOBIN DETERMINATION; HYPERTENSION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TREATMENT OUTCOME;

EID: 32944470069     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000209990.41304.43     Document Type: Article

References (24)

1. Willmot M, Leonardi-Bee J, Bath PMW. High blood pressure in acute stroke and subsequent outcome. A systematic review. Hypertension 2004; 43:18-24.
2. Giroud M, Creisson E, Fayolle H, Andre N, Becker F, Martin D, Dumas R. Risk factors for primary intracerebral hemorrhage: A population-based study - the Stroke Registry of Dijon. Neuroepidemiology 1995; 14:20-26.
3. Cechetto DF, Wilson JX, Smith KE, Wolski D, Silver MD, Hachinski VC. Autonomic and myocardial changes in middle cerebral artery occlusion: stroke models in the rat. Brain Res 1989; 502:296-305.
4. Jansen PA, Thien T, Gribnau FW, Schulte BP, Willemsen JJ, Lamers K, Poels EF. Blood pressure and both venous and urinary catecholamines after cerebral infarction. Clin Neurol Neurosurg 1988; 90:41-45.
5. Orlandi G, Fannucchi S, Strata G, Pataleo L, Landucci Pellegrini L, Prontera C, et al. Transient autonomic nervous system dysfunction during hyperacute stroke. Acta Neurol Scand 2000; 102:317-321.
6. International Society of Hypertension (ISH): Statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21:665-672.
7. Yatsu FM, Zivin J. Hypertension in acute ischemic strokes. Not to treat. Arch Neurol 1985; 42:999-1000.
8. Spence JD, Del Maestro RF. Hypertension in acute ischemic strokes: treat. Arch Neurol 1985; 42:1000-1002.
9. Johnston KC, Mayer SA. Blood pressure reduction in ischemic stroke. A two-edged sword? Neurology 2003; 61:1030-1031.
10. Adams HP, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34:1056-1083.
11. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG, for the IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315-1320.
12. Chamorro A, Vila N, Ascaso C, Elices E, Schonewille W, Blanc R. Blood pressure and functional recovery in acute ischemic stroke. Stroke 1998; 29:1850-1853.
13. Zea Longa E, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy. Stroke 1989; 20:84-91.
14. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bratowski J. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986; 17:472-476.
15. Hilali HM, Simpkins AN, Hill WD, Waller JL, Knight RA, Fagan SC. Single slice method for quantification of hemorrhagic transformation using Direct ELISA. Neurol Res 2004; 26:93-98.
16. Bowes MP, Zivin JA, Thomas GR, Thibodeaux H, Fagan SC. Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp Neurol 1996; 141:40-46.
17. Fagan SC, Bowes MP, Lyden PD, Zivin JA. Acute hypertension promotes hemorrhagic infarction in a rabbit embolic stroke model. Effect of labetalol. Exp Neurol 1998; 150:153-158.
18. Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator. Evaluation of role of hypertension with rat thromboembolic stroke model. Stroke 2001; 32:1336-1340.
19. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, Schulz R. The angiotensin II type 1 receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2004; 24:467-474.
20. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischemia in rats. J Hypertens 2003; 21:2175-2182.
21. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT1 receptors improves neurologic outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391-2399.
22. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110:843-848.
23. Kusaka I, Kusaka G, Zhou C, Ishikawa M, Nanda A, Grnager DN, et al. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. Am J Physiol Heart Circ Physiol 2004; 286:H2442-H2451.
24. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al., on behalf of the ACCESS study group. The ACCESS study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699-1703.